Acute effects of COREXIT® EC9500A on cardiovascular function
abstract published in 2011
Press Enter · cited answer in seconds
0 sources
Summary
Acute effects of COREXIT® EC9500A on cardiovascular function is a scholarly conference abstract[1].
Key Facts
- Acute effects of COREXIT® EC9500A on cardiovascular function authored Vincent Castranova[2].
- Acute effects of COREXIT® EC9500A on cardiovascular function authored David G. Frazer[3].
- Acute effects of COREXIT® EC9500A on cardiovascular function authored Jenny R. Roberts[4].
- Acute effects of COREXIT® EC9500A on cardiovascular function authored W. Travis Goldsmith[5].
- Acute effects of COREXIT® EC9500A on cardiovascular function authored Kristine M. Krajnak[6].
- Acute effects of COREXIT® EC9500A on cardiovascular function authored Hong Kan[7].
- Acute effects of COREXIT® EC9500A on cardiovascular function's instance of is recorded as scholarly conference abstract[8].
- Acute effects of COREXIT® EC9500A on cardiovascular function's page is recorded as 1016.2[9].
- Acute effects of COREXIT® EC9500A on cardiovascular function's DOI is recorded as 10.1096/FASEBJ.25.1_SUPPLEMENT.1016.2[10].
- Acute effects of COREXIT® EC9500A on cardiovascular function's language of work or name is recorded as English[11].
- Acute effects of COREXIT® EC9500A on cardiovascular function's issue is recorded as Meeting Abstracts[12].
- Acute effects of COREXIT® EC9500A on cardiovascular function's volume is recorded as 25[13].
- Acute effects of COREXIT® EC9500A on cardiovascular function's publication date is recorded as +2011-04-10T00:00:00Z[14].
- Acute effects of COREXIT® EC9500A on cardiovascular function's sponsor is recorded as NIOSH Health Effects Laboratory Division[15].
- Acute effects of COREXIT® EC9500A on cardiovascular function's main subject is recorded as Polysorbate 80[16].
- Acute effects of COREXIT® EC9500A on cardiovascular function's main subject is recorded as docusate sodium[17].
- Acute effects of COREXIT® EC9500A on cardiovascular function's main subject is recorded as polysorbate 85[18].
- Acute effects of COREXIT® EC9500A on cardiovascular function's main subject is recorded as 1-(2-butoxy-1-methylethoxy)propan-2-ol[19].
- Acute effects of COREXIT® EC9500A on cardiovascular function's main subject is recorded as sorbitan monooleate[20].
- Acute effects of COREXIT® EC9500A on cardiovascular function's main subject is recorded as hydrotreated kerosene[21].
- Acute effects of COREXIT® EC9500A on cardiovascular function's main subject is recorded as exposure assessment[22].
- Acute effects of COREXIT® EC9500A on cardiovascular function's main subject is recorded as cardiovascular disease[23].
- Acute effects of COREXIT® EC9500A on cardiovascular function's main subject is recorded as C13-C14 isoparafin[24].
- Acute effects of COREXIT® EC9500A on cardiovascular function's work available at URL is recorded as https://www.fasebj.org/doi/10.1096/fasebj.25.1_supplement.1016.2[25].
- Acute effects of COREXIT® EC9500A on cardiovascular function's published in is recorded as FASEB Journal[26].
Body
Designation and Status
Acute effects of COREXIT® EC9500A on cardiovascular function's instance of is recorded as scholarly conference abstract[8].